Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e749-e756. doi: 10.1210/clinem/dgaa871.
Hypothyroidism is associated with reversible decline in kidney function as measured by estimated glomerular filtration rate (eGFR). eGFR and proteinuria are the most important markers for clinical assessment of kidney function. Though hypothyroidism is associated with proteinuria in cross-sectional data, the impact of treatment on proteinuria is unknown.
This study explores the effect of thyroid hormone replacement therapy on eGFR and 24-hour urine protein excretion in patients with severe primary hypothyroidism.
This study was a prospective, observational cohort study in adults with severe primary hypothyroidism (serum thyrotropin [TSH] > 50 µIU/mL). Individuals with preexisting or past kidney disease, kidney or urinary tract abnormalities, calculi or surgery, diabetes mellitus, or hypertension were excluded. The participants received thyroid hormone replacement therapy. Thyroid functions, eGFR, 24-hour urine protein excretion, and biochemical parameters were measured at baseline and 3 months.
This study took place at a single center, a tertiary care referral and teaching hospital.
Of 44 enrolled participants, 43 completed 3 months of follow-up. At 3 months, serum TSH levels decreased and thyroxine levels increased (P < .001 for both). Significant increases in eGFR (mean difference, 18.25 ± 19.49 mL/min/1.73 m2; 95% CI, 12.25 to 24.25, P < .001) and declines in 24-hour urine protein excretion (mean difference, -68.39 ± 125.89 mg/day; 95% CI, -107.14 to -29.65, P = .001) were observed. Serum cholesterol and low-density lipoprotein levels also significantly decreased (P < .001).
Thyroid hormone replacement therapy in patients with severe primary hypothyroidism improves eGFR and decreases 24-hour urine protein excretion, thereby suggesting reversible alterations.
甲状腺功能减退症与估算肾小球滤过率(eGFR)测定的肾功能可逆下降有关。eGFR 和蛋白尿是评估肾功能的最重要临床指标。尽管横断面数据显示甲状腺功能减退症与蛋白尿有关,但治疗对蛋白尿的影响尚不清楚。
本研究探讨甲状腺激素替代治疗对严重原发性甲状腺功能减退症患者 eGFR 和 24 小时尿蛋白排泄的影响。
这是一项前瞻性、观察性队列研究,纳入了严重原发性甲状腺功能减退症(血清促甲状腺激素[TSH]>50µIU/mL)的成年人。排除了有既往或过去肾脏疾病、肾脏或泌尿道异常、结石或手术、糖尿病或高血压的患者。参与者接受甲状腺激素替代治疗。在基线和 3 个月时测量甲状腺功能、eGFR、24 小时尿蛋白排泄和生化参数。
这项研究在一家单中心、三级保健转诊和教学医院进行。
在纳入的 44 名参与者中,有 43 名完成了 3 个月的随访。在 3 个月时,血清 TSH 水平下降,甲状腺素水平升高(两者均 P<0.001)。eGFR 显著增加(平均差异,18.25±19.49mL/min/1.73m2;95%CI,12.25 至 24.25,P<0.001),24 小时尿蛋白排泄减少(平均差异,-68.39±125.89mg/天;95%CI,-107.14 至-29.65,P=0.001)。血清胆固醇和低密度脂蛋白水平也显著降低(P<0.001)。
甲状腺激素替代治疗严重原发性甲状腺功能减退症可改善 eGFR 并减少 24 小时尿蛋白排泄,表明存在可逆改变。